Dec 9, 2015

The Daily Startup: Vaccine Maker PaxVax Picks Up $105 Million

Private-equity firm Cerberus Capital Management has invested $105 million in PaxVax Inc., a maker of specialty vaccines, Amy Or reports for Dow Jones VentureWire. The private-equity firm will hold a majority stake of the company’s shares after the deal closes....

Nov 30, 2015

The New Vaccine Legend of Bern

PaxVax, founded in 2007, is an American specialty vaccine company with its headquarters in Redwood City, California. In 2014 the life sciences firm acquired PaxVax Berna in Thörishaus in the Canton of Bern. As a result of this purchase the...

Sep 1, 2015

Biotech in Switzerland – The Success Story of Paxvax

This July, PaxVax celebrated its first anniversary since expanding to Switzerland. It was the perfect time to talk to the company's CEO, Nima Farzan, about the many business decisions that went into this important acquisition. On a recent afternoon, he...

Jan 15, 2015

PaxVax ready to strike M&A deals that prove its sales model, CEO says

PaxVax entered the M&A arena last summer, nabbing typhoid vaccine Vivotif from Johnson & Johnson subsidiary Crucell. And it's not stopping there, CEO Ken Kelley says. The California company has another specialty travel vaccine deal coming that it's currently negotiating,...

Sep 3, 2014

VaccineNation Names PaxVax CTO Dr. Thomas Monath #2 Most Influential Person in Vaccines

VaccineNation, a leading provider of news and analysis on the vaccine industry, today announced their ranking of the fifty most influential people in vaccines. From a pool of more than 100 nominations, the publication and its readers ranked PaxVax Chief...

Jul 3, 2014

Cholera vaccine developer PaxVax passes key test

A single-dose experimental cholera vaccine from passed a key test toward becoming the only vaccine for U.S. residents traveling abroad.

May 19, 2014

Cholera Vaccine Test May Help Travelers

A California outfit, PaxVax, is conducting the trial as it seeks approval from the Food and Drug Administration to market this version to American travelers heading to high-risk areas.

Dec 11, 2013

Love in the Time of Cholera Vaccine

In any relationship, whether between two people or between individuals and germs, there are inevitably matches that are simply tragic...An American company called PaxVax has just announced that their oral, single dose and rapid-acting travellers’ vaccine, PXVX0200, has just entered...

Oct 14, 2013

Government Shutdown Muffles Biotech Sector’s Stock Boom

San Diego vaccine company PaxVax Inc. has begun a phase 3 round of clinical trials, conducting what’s called a “challenge study” among healthy volunteers ages 18 to 49 at three research hospitals — University of Maryland, University of Vermont and...

Sep 9, 2013

High ‘Cholera Sell’? Vouching for Paxvax’s Phase III Strategy

Paxvax Inc.’s just-begun Phase III effort with PXVX0200 could lead to the first cholera vaccine approved for marketing in the U.S., and the company could become the first to gauge the resale value of the FDA’s priority review voucher (PRV),...

Aug 13, 2013

Biotech Nation with Dr. Moira Gunn and PaxVax CEO, Ken Kelley

Biotech company started on a cocktail napkin - and addressing a challenge to get 6.5 billion people vaccinated in less than 120 days and for less than $1 a dose. (Interview with Dr. Moira Gunn and Ken Kelley begins at...

2 of 3123